Search

Your search keyword '"Raizes E"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Raizes E" Remove constraint Author: "Raizes E"
67 results on '"Raizes E"'

Search Results

1. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study

2. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey

3. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: A modelling study

4. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

5. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011

6. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

7. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

8. Sustainable HIV treatment in Africa through viral-load-informed differentiated care

9. Sustainable HIV treatment in Africa through viral-load-informed differentiated care

10. WEAD0302: Total Control of Epidemic (TCE) program of Humana People to People: a community driven response to the fight against AIDS

11. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis

12. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

13. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011

14. In-vitro activity of cefpirome compared with that of other agents.

15. Genotyping performance evaluation of commercially available HIV-1 drug resistance test.

16. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011

17. Beyond the 95s: What happens when uniform program targets are applied across a heterogenous HIV epidemic in Eastern and Southern Africa?

18. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.

19. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.

21. Pharyngeal Co-Infections with Monkeypox Virus and Group A Streptococcus, United States, 2022.

22. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

23. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022.

24. Ocular Monkeypox - United States, July-September 2022.

25. Drug resistance and use of long-acting ART.

26. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.

27. Pretreatment Human Immunodeficiency Virus (HIV) Drug Resistance Among Treatment-Naive Infants Newly Diagnosed With HIV in 2016 in Namibia: Results of a Nationally Representative Study.

28. Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir.

29. PEPFAR's Role in Protecting and Leveraging HIV Services in the COVID-19 Response in Africa.

31. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years - United States, August 2020-August 2021.

32. HIV drug resistance among adults initiating antiretroviral therapy in Uganda.

33. Finding, treating and retaining persons with HIV in a high HIV prevalence and high treatment coverage country: Results from the Botswana Combination Prevention Project.

34. Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes.

35. HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey.

36. Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.

37. Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.

38. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.

39. Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study.

40. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana.

41. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.

42. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

44. Pretreatment HIV drug resistance among adults initiating ART in Namibia.

45. Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings.

46. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey.

47. Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon.

48. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

49. Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.

50. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Catalog

Books, media, physical & digital resources